Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CDT Equity Inc. (NASDAQ: CDT) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on CDT’s corporate actions, financial reporting, governance decisions, and strategic developments as it operates as a data-driven biopharmaceutical development company.
CDT’s current reports on Form 8-K include items such as the approval and implementation of reverse stock splits, amendments to its certificate of incorporation, and the formal change of its corporate name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. Filings also describe stockholder approvals related to the company’s stock incentive plan, the authorization of additional shares for equity awards, and matters voted on at annual and special meetings.
Other 8-K filings address topics like non-reliance on previously issued interim financial statements and planned restatements. For example, CDT has reported on the reclassification of certain milestone payments to Sarborg Limited from research and development expense to an acquired diagnostic asset, explaining how this affects its condensed consolidated financial statements. These disclosures help readers understand how the company applies accounting standards to its AI and diagnostic-related agreements.
Proxy materials, such as definitive proxy statements on Schedule 14A, provide further insight into CDT’s governance structure, director elections, auditor ratification, and proposals to amend stock plans. They also outline voting requirements, quorum definitions, and procedural details for virtual annual meetings.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, making it easier to interpret complex sections of 10-Ks, 10-Qs, 8-Ks, and proxy statements. Real-time updates from EDGAR ensure that new CDT filings, including any Form 4 insider transaction reports or future registration statements, are quickly reflected. This allows investors and researchers to review CDT’s regulatory history, corporate actions, and reporting practices in a structured, accessible format.
CDT amends its prospectus supplement to increase the amount of common stock that may be sold under its Sales Agreement with A.G.P./Alliance Global Partners to $76,077,218 as of April 2, 2026. This Amendment upgrades the previously stated offering capacity of $3,556,586 to the larger aggregate amount because the company’s public float exceeded $75.0 million as of March 24, 2026, allowing use of General Instruction I.B.1 of Form S-3. The prospectus notes the company is an emerging growth company and a smaller reporting company, and discloses a last reported sale price of $5.10 per share on April 1, 2026.
CDT Equity Inc. filed a Form 12b-25 notifying the SEC that it could not timely file its Annual Report on Form 10-K for the period ended December 31, 2025. The company expects to file the Form 10-K on or before the fifteenth calendar day following the prescribed due date. CDT Equity anticipates a net loss of approximately $39.1 million for 2025, an increase of about $21.3 million versus 2024; these amounts remain under review by its independent registered public accounting firm.
CDT Equity Inc. reported indirect restructuring transactions involving entities associated with Mark Taylor. On February 19, 2026, Prospect Finance Limited transferred 46,902 shares of Common Stock and pre-funded warrants to purchase 9,968,931 shares of Common Stock to a third party for no consideration.
Following stockholder approval at a special meeting, on March 17, 2026 Prospect Capital Securities Limited and Prospect Finance Limited cashlessly exercised all of their remaining Pre-Funded Warrants and received 36,544,028 and 14,876,330 CDT Equity Common shares, respectively. Mark Taylor is the sole director and shareholder of both entities and may be deemed to beneficially own these securities, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
CDT Equity Inc. filed an initial ownership report showing that Prospect Capital Securities Limited and Prospect Finance Limited hold Common Stock and Pre-Funded Warrants received as consideration in a Securities Purchase Agreement dated February 19, 2026, related to Sarborg Limited.
Prospect Capital received 198,749 shares of Common Stock and Pre-Funded Warrants to purchase up to 36,551,817 shares of Common Stock in exchange for 339 Sarborg shares. Prospect Finance received 127,209 shares of Common Stock and Pre-Funded Warrants to purchase up to 24,578,432 shares in exchange for 218 Sarborg shares.
The Pre-Funded Warrants have an exercise price of $0.0001 per share, are subject to shareholder approval and a 49.99% beneficial ownership limitation, have no expiration date, and will be exercisable once approved until exercised in full. Mark Taylor, as sole director and shareholder of both entities, may be deemed to beneficially own these securities, but disclaims beneficial ownership except to the extent of his pecuniary interest.
CDT Equity Inc. now has a major shareholder group after its acquisition of a 20% stake in Sarborg Limited. Prospect Capital Securities Ltd and Prospect Finance Ltd received 598,006 CDT common shares and pre-funded warrants for up to 109,978,918 shares as consideration. Following shareholder approval and cashless exercise of all pre-funded warrants, Prospect Capital holds 36,742,777 shares (31.12%) and Prospect Finance holds 14,957,237 shares (12.67%). Through these vehicles, Mark Taylor may be deemed to beneficially own 51,700,014 shares, or 43.79% of CDT’s 118,061,466 shares outstanding as of March 19, 2026.
CDT Equity Inc. is implementing a 1-for-25 reverse stock split of its common stock. The split becomes effective on March 26, 2026 at 5:00 p.m. Eastern Time, with trading on a split-adjusted basis on Nasdaq starting March 27, 2026 under the same ticker, CDT.
Every 25 issued and outstanding shares will be combined into one share, while the par value remains $0.0001. The company expects its post-split outstanding common shares to be reduced to approximately 4,722,450. Outstanding equity awards, convertible securities and warrants, as well as plan reserves and exercise prices, will be adjusted proportionally.
No fractional shares will be issued; stockholders otherwise entitled to fractions will receive a cash payment based on the split-adjusted closing price on March 26, 2026. The common stock will continue trading on Nasdaq with a new CUSIP 20678X502.
CDT Equity Inc. reported that stockholders approved seven proposals at a special meeting held on March 17, 2026. A quorum was present with proxies representing over one-third of common shares entitled to vote.
Stockholders approved the issuance of up to 3,685,815 shares of common stock upon exercise of certain pre-funded warrants, and separately approved the issuance of up to 109,978,918 shares upon exercise of additional pre-funded warrants, each in accordance with Nasdaq Listing Rule 5635. They also approved issuances of common stock under a January 16, 2026 equity line of credit purchase agreement.
Investors authorized one or more reverse stock splits at ratios between 1-for-2 and 1-for-100, and in the aggregate not more than 1-for-250, at the board’s discretion, as well as an increase in authorized common shares from 250,000,000 to 500,000,000. Stockholders further approved redomestication of the company from Delaware to the Cayman Islands, including adoption of new memorandum and articles of association, and authorized potential adjournment of the meeting to continue soliciting votes if needed.
CDT Equity Inc. amended its directed stock purchase agreement with an institutional investor, lowering the equity line of credit floor price to $0.60. At this level, the maximum common shares potentially issuable under the facility is 41,666,667 shares, with full issuance subject to stockholder approval under Nasdaq rules.
The company also entered into a Securities Purchase Agreement and issued a Senior Secured Convertible Promissory Note with principal of up to $555,556, bearing 10% annual interest and maturing on July 3, 2026. After stockholder approval, the investor may convert principal into common shares at the Nasdaq official closing price on the approval date, subject to a 9.99% beneficial ownership cap. The note is secured by company assets and supported by a guaranty, and both the equity line shares and conversion shares are being issued in unregistered transactions under Section 4(a)(2).
CDT Equity Inc. has called a virtual special meeting to ask stockholders to approve several major capital and structural actions. Key items include authorizing up to 3,685,815 shares from December pre-funded warrants and up to 109,978,918 shares from February pre-funded warrants, both subject to Nasdaq Listing Rule 5635.
The company also seeks approval to issue shares under a $25 million equity line of credit with Ascent Partners Fund LLC, which could represent a large portion of the current float. With 4,420,963 shares outstanding as of February 25, 2026, these issuances would be highly dilutive if fully exercised or sold.
Additional proposals would permit one or more reverse stock splits between 1‑for‑2 and, in the aggregate, up to 1‑for‑250, double authorized common shares from 250 million to 500 million, and redomesticate the company from Delaware to the Cayman Islands, changing the governing law and charter framework.
CDT Equity Inc. entered a Securities Purchase Agreement to acquire approximately 20% of Sarborg Limited in exchange for equity, warrants and future cash. The company will issue 598,006 shares of common stock and pre-funded warrants to purchase up to 109,978,918 additional shares, plus pay Sarborg $8 million in cash after it raises at least $20 million through an at-the-market program. The pre-funded warrants, priced at $0.0001 per share, are exercisable only after required stockholder approval under Nasdaq rules. CDT Equity also extended two consulting agreements, paying retainers via 199,734 shares to NJS Foresight Bio-Advisory and 341,702 shares to Thesprogen PC, and previously issued 130,000 shares to Maxim Partners LLC for investment banking services.